Navigation Links
AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma
Date:6/19/2012

d president of Discovery and Research at Rigel Pharmaceuticals.

"We are pleased to be expanding our relationship with Rigel and to develop and commercialize this novel asset, R256," said Mene Pangalos, executive vice president of Innovative Medicines at AstraZeneca. "Despite the number of medicines available to asthma patients today, there remains a need for more targeted therapies for moderate to severe chronic asthma. Through this agreement, R256 will benefit from the wealth of experience AstraZeneca has in bringing innovative treatments for respiratory diseases to millions of patients around the world."

In preclinical studies, R256, a JAK inhibitor, has been shown to be a potent inhibitor of IL-13 and IL-4 signaling at the primary cellular level. Patients with moderate to severe chronic asthma experience persistent inflammation and cellular remodeling of their airways, which may result in permanently reduced lung function if left untreated. In preclinical models, R256 reduces the severity of inflammation and improves lung function by mechanisms associated with several hallmarks of asthma such as bronchoconstriction, mucus overproduction and airway remodeling. In May 2012, Rigel presented two studies on R256 in asthma at the American Thoracic Society International Conference. 

This is the second licensing agreement between AstraZeneca and Rigel Pharmaceuticals. The companies previously announced a worldwide license agreement in February 2010, whereby AstraZeneca agreed to develop and commercialize fostamatinib, the first oral SYK inhibitor in development, as a novel therapeutic approach for rheumatoid arthritis. The Phase 3 clinical program, called OSKIRA (Oral SYK Inhibition in Rheumatoid Arthritis) enrolled its first patient in September of 2010 and is designed to investigate fostamatinib as a therapeutic option for patients who have an inadequate response to currently available therapies such as traditional disease modifyin
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
2. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
3. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
4. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
5. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
6. ResearchMoz: Oxygen Concentrator Market Shares, Strategies and Forecasts, Worldwide, 2012 to 2018
7. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
8. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
9. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
10. ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
11. HistoRx Licenses Melanoma Assay from Yale University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... IRVING, Texas , May 29, 2015 /PRNewswire/ ... company focused on fulfilling the promise of precision ... five studies that demonstrate the clinical utility of ... comprehensive tumor profiling service, in helping to identify ... aggressive tumors. In each of the studies, results ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Seoul ... leader in LED technology, on May 28th announced ... market share by strengthening its high efficient and ... application , Since 2011 Seoul Semiconductor has developed ... lighting market and has supplied LEDs for headlamps ...
(Date:5/28/2015)... 2015  Quest Diagnostics Incorporated (NYSE: DGX ), ... that it is scheduled to speak at the Jefferies ... Rusckowski , the company,s President and CEO, will discuss ... presentation is scheduled for Tuesday, June 2, 2015 at ... be webcast live during the conference and will be ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has ... "Cell Therapy - Technologies, Markets and Companies" ... describes and evaluates cell therapy technologies and methods, ... role in the practice of medicine. Hematopoietic stem ... marrow transplants. Role of cells in drug discovery ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2
... Mass., Oct. 1 Based on the clinical ... today announced,that the company has expanded its executive ... MA. "The move to Massachusetts,allows us to consolidate ... Geoff Pardo. "It also gives us access to ...
... CITY, Oct. 1, /PRNewswire-FirstCall/ - AEterna Zentaris ... global biopharmaceutical company focused on,endocrine therapy and ... for the Company,s second efficacy trial of ... (BPH), a non-cancerous enlargement of the,prostate, with ...
... DUBLIN, Ireland, October 1 Shire Limited,(LSE: SHP, NASDAQ: ... approval by shareholders at the Annual General,Meeting on September ... Shire,plc with effect from today., Shire plc,s ticker ... ISIN numbers of the Company,s Ordinary shares and American ...
Cached Biology Technology:Facet Solutions Establishes Corporate Headquarters and Expands Executive Team 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4
(Date:5/28/2015)... May 28, 2015 Industry analyst firm ... new report titled "Markets for Self-Healing Materials: 2015-2022." According ... capsule and vascular systems, biomaterials, relevant shape memory ... around $2.7 billion by 2020. The ... coverage of smart materials. Other recent n-tech reports have ...
(Date:5/26/2015)... 2015 Research and Markets ... the "Saudi Arabia Biometric Systems Market Forecast ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market ... projected to grow at over 22% CAGR through ... to the surging demand for better biometric technologies ...
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3
... 18 October 2010, Singapore A total of 15 world ... in their respective fields at the 6th Decade of the ... 20 October 2010. Jointly organised by A*STAR,s Institute of ... (DRTech) and NUS,s Temasek Laboratories, it is the first such ...
... -- Harvard University neurobiologists have created mice that can "smell" ... better understand the neural basis of olfaction. The work, ... has implications for the future study of smell and of ... study with traditional methods. "It makes intuitive sense to ...
... 22 Lockheed Martin (NYSE: LMT ) and ... system that has potential to transform how law enforcement, homeland ... their missions. The prototype, called Rap I.D .™, ... special session on Rapid DNA. The day-long session is ...
Cached Biology News:Singapore hosts first 'Decade of the Mind' conference in Asia 2Singapore hosts first 'Decade of the Mind' conference in Asia 3Mice that 'smell' light could help us better understand olfaction 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 3
... Each glass slide in this set ... antibodies in triplicate, for a total ... house-keeping proteins as internal control. Antibodies ... as angiogenesis, apoptosis, cell cycle progression, ...
...
...
... T7 Phage Capture Plate is a 96-well ELISA-compatible ... the T7 Tail Fiber Monoclonal Antibody is immobilized ... The antibody specifically recognizes the tail fiber protein ... has a capacity of 10 9 phage ...
Biology Products: